Acute Respiratory Distress Syndrome; A Review of Recent Updates and a Glance into the Future

Husayn F Ramji; Maida Hafiz; Hiba Hammad Altaq; Syed Talal Hussain; Fawad Chaudry

doi:10.3390/diagnostics13091528

Acute Respiratory Distress Syndrome; A Review of Recent Updates and a Glance into the Future

Diagnostics (Basel). 2023 Apr 24;13(9):1528. doi: 10.3390/diagnostics13091528.

Authors

Husayn F Ramji^{1

2}, Maida Hafiz³, Hiba Hammad Altaq⁴, Syed Talal Hussain⁴, Fawad Chaudry⁴

Affiliations

¹ University of Oklahoma College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
² Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
³ Department of Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
⁴ Department of Pulmonary, Critical Care & Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Abstract

Acute respiratory distress syndrome (ARDS) is a rapidly progressive form of respiratory failure that accounts for 10% of admissions to the ICU and is associated with approximately 40% mortality in severe cases. Despite significant mortality and healthcare burden, the mainstay of management remains supportive care. The recent pandemic of SARS-CoV-2 has re-ignited a worldwide interest in exploring the pathophysiology of ARDS, looking for innovative ideas to treat this disease. Recently, many trials have been published utilizing different pharmacotherapy targets; however, the long-term benefits of these agents remain unknown. Metabolomics profiling and stem cell transplantation offer strong enthusiasm and may completely change the outlook of ARDS management in the near future.

Keywords: acute respiratory distress syndrome; gut-lung microbiome; mesenchymal stem cell transplantation; metabolomics; pharmacotherapy in ARDS.

Publication types

Review

Grants and funding

This research received no external funding.